Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 140-146

  Jin, Lanying ^a   Shen, Qi ^a   Ding, Shengdi ^a   Jiang, Wenxiao ^a   Jiang, Lingling ^a   Zhu, Xueqiong ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Annexin A2; Immunohistochemistry; Neoadjuvant chemotherapy; S100A proteins; Squamous cervical cancer

Indexed keywords

CALCIUM BINDING PROTEIN; CALGRANULIN A; CALGRANULIN B; CALVASCULIN; CISPLATIN; FLUOROURACIL; LIPOCORTIN 2; MITOMYCIN C; PROTEIN S100A2; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; STROMA CELL; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; ANNEXIN A2; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; S100 PROTEINS; STROMAL CELLS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 84862757275     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.005     Document Type: Article

References (35)

1. Martin-Hirsch PL, Wood NJ. Cervical cancer. Clin Evid (Online) 2011;7:818.
2. Kim DS, Moon H, Kim KT, Hwang Y, Cho S, Kim SR. Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages IB and II with bulky tumor. Gynecol Oncol 1989;33:225-30. (Pubitemid 19112919)
3. Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997;67:61-9. (Pubitemid 27433330)
4. Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004;92:59-63. (Pubitemid 38147372)
5. Chel Hun C, Tae-Joong K, Jeong-Won L, Byoung-Gie K, Je-Ho L, Duk-soo B. II study of neoadjuvant chemotherapy with mitomycin-c vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol 2007;104:64-9.
6. Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: a randomized study. Gynecol Oncol 2008;110:308-15.
7. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem 2005;280:20833-41. (Pubitemid 40776788)
8. Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and RXR agonist treatment in melanoma cells: functional importance of S100A2. PPAR Res 2010;2010:729876.
9. Bruheim S, Xi Y, Ju J, Fodstad O. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res 2009;15:7161-9.
10. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-67. (Pubitemid 46628468)
11. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 2007;13:912-9. (Pubitemid 46340367)
12. Oloumi A, Lam W, Banath JP, Olive PL. Identification of genes differentially expressed in V79 cells grown as multicell spheroids. Int J Radiat Biol 2002;78:483-92. (Pubitemid 34680780)
13. Mencia N, Selga E, Rico I, de Almagro MC, Villalobos X, Ramirez S, et al. Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC Cancer 2010;10:250.
14. L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006;29:5-24.
15. Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 2007;6:122-7. (Pubitemid 46206674)
16. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 2009;8:47-56.
17. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005;65:10265-72. (Pubitemid 41743718)
18. Zhu H, Pei HP, Zeng S, Chen J, Shen LF, Zhong MZ, et al. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res 2009;8:3969-76.
19. WHO. Handbook for Reporting Results of Cancer Treatment. WHO, Geneva: W.H.O. Offset Publication; 1989. No. 48.
20. Konishi I, Nanbu K, Mandai M, Tsuruta Y, Kataoka N, Nagata Y, et al. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol Oncol 1998;70:365-71. (Pubitemid 28473636)
21. Saito T, Takehara M, Tanaka R, Lee R, Horie M, Wataba K, et al. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol 2004;92:284-92. (Pubitemid 38147405)
22. Costa S, Terzano P, Bovicelli A, Martoni A, Angelelli B, Santini D, et al. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2004;80:67-73.
23. Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 2006;103:1031-7. (Pubitemid 44821330)
24. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, et al. Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009;8:5041-7.
25. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2007;30:1545-51.
26. Moguen KL, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, et al. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 2006;6:5183-92. (Pubitemid 44549991)
27. Yim EK, Tong SY, Ho EM, Bae JH, Um SJ, Park JS. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol Rep 2009;21:549-57.
28. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001;21:1339-45.
29. Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B. Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol 2010;40:1203-12.
30. Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, Shimizu H, et al. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 2008;15:3157-68.
31. Salama I, Malone PS, Mihaimeed F. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008;34:357-64. (Pubitemid 351381290)
32. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007;43:1935-43. (Pubitemid 47284868)
33. Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, et al. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res 2009;69:4260-9.
34. Ha YS, Kim MJ, Yoon HY, Kang HW, Kim YJ, Yun SJ, et al. mRNA expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer. Korean J Urol 2010;51:15-20.
35. Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 2011;17:478-85.